Synthesis and crystal structure of two copper(II) complexes with coordinated decavanadate ion

Functionalization of decavanadate anion by coordination to cobalt(II): Binding to proteins, cytotoxicity, and water oxidation catalysis

A series of five decavanadates (V₁₀) using a simple, one-pot synthesis, adhering to the model template: transition metal ion - decavanadate - ligands:(Hnicotinamide)₂{[Co(H₂O)₃(nicotinamide)₂]₂[μ-V₁₀O₂₈]}.6H₂O (1), {[Co(H₂O)₄(isonicotinamide)₂]₃}V₁₀O₂₈·4H₂O (2), {[Co(H₂O)₄]₂[Co(H₂O)₂(μ-pyrazinamide)₂][μ-V₁₀O₂₈]}·4H₂O (3) {[Co(H₂O)₄(μ-pyrazinamide)]₃.V₁₀O₂₈}·4H₂O (4), and (NH₄)₂{[Ni(H₂O)₄(2-hydroxyethylpyridine)]₂}V₁₀O₂₈·2H₂O (5) was synthesized. X-ray analysis reveals that 1 and 3 are decavanadato complexes, while 2, 4 and 5 are decavanadate complex salts. Moreover, 3 is the first example of a polymeric decavanadato complex, employing direct coordination with the metal center and the organic ligand, in toto. From the solution studies using ⁵¹V NMR spectroscopy, it was decoded that 1 and 3 stay stable in the model buffer solution and aqueous media. Binding to model proteins, cytotoxicity and water oxidation catalysis (WOC) was studied primarily for 1 and 3 and concluded that neither 1 nor 3 have an interaction with the model proteins thaumatin, lysozyme and proteinase K, because of the presence of the organic ligands in the Co(II) center, any further interplay with the proteins was blocked. Cytotoxicity studies reveal that 1 is 40% less toxic (0.05 mM) and 26% less toxic (0.1 mM) than the uncoordinated V₁₀ with human cell lines A549 and HeLa respectively. In WOC, 1 performed superior activity, by evolving 143.37 nmol of O₂ which is 700% (9-fold) increase than the uncoordinated V₁₀.

Magneto-structural correlations of cyclo-tetravanadates functionalized with mixed-ligand copper(ii) complexes

Bimetallic materials based on tetravanadate anions and mixed ligand copper(ii) complexes were readily synthesized under non-hydrothermal conditions. The compounds show interesting structural and magnetic diversity mediated by copper symmetry.

Metformin-decavanadate treatment ameliorates hyperglycemia and redox balance of the liver and muscle in a rat model of alloxan-induced diabetes

MetfDeca treatment ameliorate glucose and insulin levels, and reduce the levels of oxidized glutathione, reactive oxygen species, malondialdehyde, and 4-hydroxyalkenal; the superoxide and catalase activities, and glutathione levels were regulated.

Tuning the interactions of decavanadate with thaumatin, lysozyme, proteinase K and human serum proteins by its coordination to a pentaaquacobalt(ii) complex cation

Inorganic functionalization of the decavanadate anion promotes a different type of interaction with model proteins thaumatin, lysozyme, proteinase K, human serum albumin and transferrin.

Decavanadate Salts of Cytosine and Metformin: A Combined Experimental-Theoretical Study of Potential Metallodrugs Against Diabetes and Cancer

Cytosine, a DNA and RNA building-block, and Metformin, the most widely prescribed drug for the treatment of Type 2 Diabetes mellitus were made to react separately with ammonium or sodium metavanadates in acidic aqueous solutions to obtain two polyoxovanadate salts with a 6:1 ratio of cation-anion. Thus, compounds [HCyt]6[V10O28]·4H2O, 1 and [HMetf]6[V10O28]·6H2O, 2 (where HCyt = Cytosinium cation, [C4H6N3O]+ and HMetf = Metforminium cation, [C4H12N5]+) were obtained and characterized by elemental analysis, single crystal X-ray diffraction, vibrational spectroscopy (IR and Raman), solution 51V-NMR, thermogravimetric analysis (TGA-DTGA), as well as, theoretical methods. Both compounds crystallized in P1 ¯   space group with Z' = 1/2, where the anionic charge of the centrosymmetric ion [V10O28]6- is balanced by six Cytosinium and six Metforminium counterions, respectively. Compound 1 is stabilized by π-π stacking interactions coming from the aromatic rings of HCyt cations, as denoted by close contacts of 3.63 Å. On the other hand, guanidinium moieties from the non-planar HMetf in Compound 2 interact with decavanadate μ2-O atoms via N-H···O hydrogen bonds. The vibrational spectroscopic data of both IR and Raman spectra show that the dominant bands in the 1000-450 cm-1 range are due to the symmetric and asymmetric ν(V-O) vibrational modes. In solution, 51V-NMR experiments of both compounds show that polyoxovanadate species are progressively transformed into the monomeric, dimeric and tetrameric oxovanadates. The thermal stability behavior suggests a similar molecular mechanism regarding the loss of water molecules and the decomposition of the organic counterions. Yet, no changes were observed in the TGA range of 540-580°C due to the stability of the [V10O28]6- fragment. Dispersion-corrected density functional theory (DFT-D) calculations were carried out to model the compounds in aqueous phase using a polarized continuum model calculation. Optimized structures were obtained and the main non-covalent interactions were characterized. Biological activities of these compounds are also under investigation. The combination of two therapeutic agents opens up a window toward the generation of potential metalopharmaceuticals with new and exciting pharmacological properties.

Tetrakis(2,6-di-methyl-pyridinium) di-hydrogen deca-vanadate dihydrate

The structure of the title compound, (C₇H₁₀N)₄[H₂V₁₀O₂₈]·2H₂O, was solved from a non-merohedrally twinned crystal (ratio of twin components ∼0.6:0.4). The asymmetric unit consists of one-half deca­vanadate anion (the other half completed by inversion symmetry), two 2,6-di­methyl­pyridinium cations and one water mol­ecule of crystallization. In the crystal, the components are connected by strong N—H⋯O and O—H⋯O hydrogen bonds, forming a supra­molecular chain along the b-axis direction. There are weak C—H⋯O inter­actions between the chains.